Question 10978 — maternity health insurance

Summary

Ms Émilie Guerel draws the attention of the Minister of Solidarity and Health to the absence of coverage by social security of TCAPS as part of the treatment of hypothyroidism. TCAPS, introduced in pharmacies in April 2018, is an alternative medication to Levothyrox. In France, Levothyrox is an essential synthetic hormone prescribed to three million people. The new formula of the drug, marketed in March 2017, caused numerous adverse effects, reported by 17,310 French patients in November 2017. This is why TCAPS seems better suited to people with hypersensitivity to certain excipients. Today it is essential to maintaining good health, when it must be taken for life. However, unlike the old Levothyrox formulas, TCAPS is currently not reimbursed by social security. In addition, the price, set freely by pharmacies, varies significantly from one structure to another, according to the French Association of Thyroid Patients. Thus, she would like to know if the Government plans to guarantee the reimbursement of TCAPS by social security instead of Levothyrox, and if not, if it intends to take broader actions on the subject of reimbursement of medicines intended for the treatment of hypothyroidism.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.